## ⚠ Content Warning This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here. --- last_verified: "2026-05-19T19:11:09.980Z" --- schema_type: "SoftwareApplication" entity_type: "Mobile Application" app_name: "Cuspart: Blood Sugar" developer_entity: "Mustafa Tolga DALBUDAK" bundle_id: "com.kan-sayimi-glukoz" app_store_id: "6445853132" google_play_id: "com.kansayimi.glukoz" category: "Medical" primary_platform: "ios" primary_monetization: "Freemium" offline_capable: true market_region: "US" platforms: "iOS & Android" app_last_updated: "2026-04-15" report_date: "2026-05-19" last_verified: "2026-05-19" report_version: "1.33.4552" total_reviews: 1 overall_rating: 5 confidence: "low" confidence_score: 0.2 data_age_days: 0 momentum_velocity: "maintenance" intelligence_version: 4 nemesis: "Shotsy GLP-1 Tracker" competitor_count: 11 tags: ["medical", "freemium", "mobile app", "app review", "app analysis", "individuals", "managing", "diabetes"] canonical_url: "https://marlvel.ai/intel-report/medical/cuspart-blood-sugar" license: "CC-BY-NC 4.0" content_version: "v2" --- # Cuspart: Blood Sugar App Audit ## TL;DR {#tldr} - **Category**: Medical · Freemium - **Signal**: Rating 5 > **TL;DR:** Cuspart: Blood Sugar is a medical app by Mustafa Tolga DALBUDAK, rated 5/5 by 1 users, available on iOS & Android. > > **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence. > **Key Insight:** Cuspart: Blood Sugar is a medical app by Mustafa Tolga DALBUDAK. ## Quick Facts | Fact | Value | | :--- | :--- | | **Rating** | 5/5 (1 reviews) | | **Category** | Medical | | **Developer** | Mustafa Tolga DALBUDAK | | **Pricing** | Freemium | | **Platforms** | iOS & Android | | **Confidence** | Low (0.2/1.0) | | **Data Age** | 0d | ## Metadata & Market Performance - **Publisher:** Mustafa Tolga DALBUDAK - **Category:** Medical - **Target Audience:** Individuals managing diabetes or glucose levels who require a private, offline-capable tool for health tracking and clinical reporting. - **Platforms:** iOS & Android - **Version Audited:** 1.33.4552 - **Audit Date:** 2026-05-19 - **Signal Count:** 0 reviews analyzed - **Confidence:** Low (0.2/1.0) - **App Store ID (iOS):** 6445853132 - **Bundle ID:** com.kan-sayimi-glukoz - **Google Play ID:** com.kansayimi.glukoz - **Performance Trend:** Mixed - **Data Window:** Analysis based on signals collected up to 2026-05-19 - **Short Description:** Diabetes & Glucose Tracker ## Executive Snapshot **What it is:** Cuspart is a medical tracking app for diabetes management that uses a local-first, one-time payment model on iOS and Android. **Why users hire it:** Users hire Cuspart to maintain clinical health records without the privacy risks or recurring costs associated with cloud-synced medical trackers. ## App DNA (Features & Intent) - **[Differentiator] Offline Data Logging:** Log glucose, insulin, and vitals without an active internet connection * *User Intent:* Users want uninterrupted access without internet dependency. - **[Standard] Professional PDF/CSV Reporting:** Generate and share health history reports for physician review * *User Intent:* Users seek social connection and competitive engagement with peers. - **[Differentiator] Local Data Privacy:** Store all health data locally on the device rather than on external servers * *User Intent:* Users prioritize data protection and trust in the platform. ## Market Position {#market-position} Cuspart maintains a niche position in the medical category by prioritizing local data storage over the cloud-sync features standard in the top 10 health trackers. ## Monetization Strategy - **Model:** Freemium - **Tiers:** Free tier with core tracking features, Pro tier via one-time payment for full offline functionality - **Analysis:** Freemium model utilizing a one-time purchase to unlock offline capabilities, avoiding recurring subscription fatigue. ## SWOT Analysis {#swot} **Core Strengths:** - Local-only data architecture eliminates cloud-based security risks - One-time purchase model removes recurring subscription friction **Critical Frictions:** - Zero Android rating count indicates low platform penetration - Manual logging requirement increases user friction vs CGM-integrated rivals **Growth Levers:** - Develop Apple Health and Google Fit integration to reduce manual entry - Target privacy-conscious users migrating from cloud-heavy competitors **Market Threats:** - Shotsy's predictive medication modeling creates higher clinical value - Gluroo's wearable-first data visualization drains the high-tech user segment ## Recent Changes (v3 → v4) {#recent-changes} The competitive outlook shifted to address specific high-velocity rivals and the failure of the Android launch to generate user feedback. **Overall trend**: Mixed **Compared at**: 2026-05-19 ### High-impact changes - **[Shifted] Competitive Threat Landscape** (swot) — Replaced generic market threats with specific competitor risks: Shotsy's predictive medication modeling and Gluroo's wearable-first data visualization. ### Medium-impact changes - **[Added] Android Platform Weakness** (swot) — Added zero Android rating count as a specific weakness, indicating low platform penetration post-launch. - **[] B2B Distribution Barrier** (positioning) — Refined the privacy-first positioning from a consumer benefit to a mechanism for bypassing HIPAA compliance hurdles in clinical partnerships. - **[Added] Android Onboarding Audit** (swot) — Added a new PM action item to audit the Android onboarding flow due to the total lack of user ratings since the April 2026 launch. ## Rivals Landscape {#rivals} > Competitive positioning identified by AI analysis of app features, category, and market signals. ### Cuspart: Blood Sugar vs Shotsy GLP-1 Tracker — Head to Head - **[Shotsy GLP-1 Tracker](https://marlvel.ai/intel-report/health-fitness/com-everyday-shottracker)** by Shotsy: Shotsy directly competes for the same chronic condition management audience by focusing on medication adherence and glucose trends, mirroring Cuspart's goal of simplifying complex health data. - **Key differences:** - Offers sophisticated medication level estimation which provides deeper clinical context than simple manual logging tools - Maintains a high-velocity release cadence with five updates in six months, ensuring superior platform stability - Leverages massive social proof and user volume to dominate search visibility within the health category - **Where Cuspart: Blood Sugar wins:** - ✅ Focuses on a broader diabetes management scope rather than just GLP-1 specific medication tracking - ✅ Provides a more streamlined, singular interface for users who find complex medication trackers overwhelming - **Where Shotsy GLP-1 Tracker wins:** - ❌ Advanced predictive modeling for medication levels creates a sticky, high-value user experience - ❌ Extensive Apple Health integration provides a more comprehensive ecosystem data loop for users - **Verdict:** Cuspart must prioritize deep Apple Health integration and predictive data visualization to prevent users from migrating to Shotsy's more robust analytical suite. ### Contenders (Strong Challengers) - **[Carb Unit Diary for Diabetics](https://marlvel.ai/intel-report/medical/carb-unit-diary-for-diabetics)** by Jommi UG (haftungsbeschrankt): Directly addresses the carbohydrate tracking needs of diabetic users, serving as a functional alternative for diet-focused glucose management. - Specializes in carb unit tracking, a specific metric highly valued by users managing insulin dosages - Lacks recent updates, creating a significant opportunity for Cuspart to capture users seeking modern features - **[Low-Carb Diet & Meal Planner](https://marlvel.ai/intel-report/medical/low-carb-diet-meal-planner)** by Jommi UG (haftungsbeschrankt): Targets the dietary management aspect of diabetes care, competing for users who prioritize food intake logging over clinical tracking. - Focuses exclusively on nutritional lookup and meal building rather than broader clinical health data tracking - Operates on an outdated UI framework that lacks the modern, clean aesthetic of current health apps - **[Medisafe Carezone: PillMemo](https://marlvel.ai/intel-report/medical/medisafe-carezone-pillmemo)** by Marcin Jedrzejak: Competes on the medication management front, offering robust inventory and notification features that overlap with Cuspart's tracking capabilities. - Includes advanced inventory management features that help users track remaining medication supply levels effectively - Provides built-in health sharing capabilities, allowing users to easily export data to caregivers or physicians - **[GLP 1 Tracker - Within Reach](https://marlvel.ai/intel-report/health-fitness/glp-1-tracker-within-reach)** by CoreBits LLC: This app targets the same niche of GLP-1 users but emphasizes privacy and local-first data storage as a primary value proposition. - Prioritizes local-first data storage, appealing to privacy-conscious users wary of cloud-based health data syncing - Integrates Siri voice commands to reduce friction in logging medication and glucose levels on-the-go ### Peers (What They Do Better) - **[Gluroo CGM Analog Watchface](https://marlvel.ai/intel-report/health-fitness/gluroo-cgm-analog-watchface)** by Gluroo Imaginations Inc.: Focuses on the wearable hardware aspect of glucose monitoring, competing for the same user's wrist real estate. - Provides direct CGM data visualization on watch faces, eliminating the need to open a phone app - Includes specific support for Omnipod 5, catering to a highly technical and specific user segment - **[Staging Diabetes Logger](https://marlvel.ai/intel-report/health-fitness/staging-diabetes-logger)** by Gluroo Imaginations Inc.: Shares the same core mission of comprehensive diabetes logging but differentiates through collaborative features. - Enables 'Glucrew' collaboration, allowing multiple users to monitor and support a single patient's health data - Provides cross-platform support including Wear OS, expanding accessibility beyond the iOS-only target audience - **[Bread Units Calculator System](https://marlvel.ai/intel-report/health-fitness/bread-units-calculator-system)** by Jommi UG (haftungsbeschrankt): Provides a legacy utility for bread unit calculations, competing for the same diabetic demographic. - Offers a highly specialized, singular utility for bread unit calculation without broader health tracking - Minimalist feature set makes it a low-threat alternative for users needing only basic math tools - **[GotCGM](https://marlvel.ai/intel-report/health-fitness/gotcgm)** by Gluroo Imaginations Inc.: Targets the same user base by focusing on real-time CGM data integration and Apple ecosystem connectivity. - Supports Live Activities and CarPlay, offering superior glanceable data access for users on the move - Deep calendar integration allows users to correlate glucose spikes with specific scheduled daily events ### New Kids on the Block (What's Innovative) - **[Pill Reminder: Med-Alarm](https://marlvel.ai/intel-report/health-fitness/pill-reminder-med-alarm)** by Ramkumar Vellaisamy: A fresh competitor in the medication adherence space, challenging Cuspart's tracking utility with a focus on simplicity. - Employs a privacy-first architecture that appeals to users concerned about health data security and tracking - **[Kickoff: Weight Loss & Fitness](https://marlvel.ai/intel-report/health-fitness/kickoff-weight-loss-fitness)** by Andy Arevalo: A new entrant focusing on the intersection of weight loss and fitness, which often overlaps with diabetes management goals. - Introduces gamified team modes to increase user retention through social accountability and competitive fitness tracking ## What's New - **Latest (v1.1.3434, 2 years ago):** General performance improvements and stability updates. ## App Momentum (Maintenance) {#momentum} - Launched Android version in April 2026. - Maintains one-time purchase model. > **Cadence:** 5 total versions · 2 majors in last 6 months · 33 days since last update · 104 days avg between updates ## The "So What?" (Strategic Takeaway) {#so-what} Cuspart: Blood Sugar is an established medical app that is free with in-app purchases. With a 5/5 rating from 1 reviews, it shows polarized user reception. > **Bottom Line:** Cuspart secures a privacy-focused niche through its local-first architecture, but the lack of automated CGM integration limits its long-term retention against hardware-connected rivals, so the PM must prioritize ecosystem data syncing to remain competitive. **Best for:** Individuals managing diabetes or glucose levels who require a private, offline-capable tool for health tracking and clinical reporting. ### PM Action Plan (Next Best Moves) - [ ] [INVEST] [HIGH IMPACT] Ship Apple Health and Google Fit integration because manual logging is the primary friction point → increase daily retention — *Competitors like Shotsy leverage ecosystem data loops to provide superior value.* _(trade-off: deprioritize Deprioritize the UI redesign of the reporting module — data utility outweighs aesthetic updates.)_ - [ ] [PIVOT] [MEDIUM IMPACT] Audit Android onboarding flow because the platform has zero ratings since launch → improve conversion — *The Android version launched in April 2026 but has failed to generate any user feedback.* _(trade-off: deprioritize Pause the development of new chart visualization types — current charts are sufficient for core utility.)_ ### Feature Gaps vs Competitors - Automated CGM integration (available in GotCGM but missing here) - Predictive medication level estimation (available in Shotsy but missing here) - Collaborative caregiver monitoring (available in Staging Diabetes Logger but missing here) ### Outlook: Mixed The medical tracking market is consolidating around apps that offer automated wearable integration, leaving manual-entry tools like Cuspart increasingly exposed. The PM must transition from a manual-logging utility to an integrated health hub to prevent user migration to hardware-connected competitors. - 🟢 The recent Android launch expands the addressable market, allowing the app to capture users outside the iOS-only segment. - 🔴 The total lack of Android ratings post-launch suggests low discovery or high friction in the initial user funnel. ## Key Metrics Summary | Metric | Value | | :--- | :--- | | Overall Rating | 5/5 | | Total Reviews | 1 | | Confidence | Low | | Pricing Model | Freemium | | Platforms | iOS & Android | | Key Features | 3 analyzed | | Trend | Mixed | | Outlook | Mixed | ## Competitor Comparison | App | Rating | Sentiment | Developer | | :--- | :--- | :--- | :--- | | **Cuspart: Blood Sugar** (this app) | 5/5 | N/A | Mustafa Tolga DALBUDAK | | [Shotsy GLP-1 Tracker](https://marlvel.ai/intel-report/health-fitness/com-everyday-shottracker) | 4.8/5 | Excited | Shotsy | | [GLP 1 Tracker - Within Reach](https://marlvel.ai/intel-report/health-fitness/glp-1-tracker-within-reach) | 4.8/5 | Thrilled | CoreBits LLC | | [Kickoff: Weight Loss & Fitness](https://marlvel.ai/intel-report/health-fitness/kickoff-weight-loss-fitness) | N/A/5 | N/A | Andy Arevalo | | [Carb Unit Diary for Diabetics](https://marlvel.ai/intel-report/medical/carb-unit-diary-for-diabetics) | 4.2/5 | N/A | Jommi UG (haftungsbeschrankt) | | [Low-Carb Diet & Meal Planner](https://marlvel.ai/intel-report/medical/low-carb-diet-meal-planner) | 3.3/5 | N/A | Jommi UG (haftungsbeschrankt) | ## Company Profile - **Developer:** Mustafa Tolga DALBUDAK - **Website:** [https://www.cuspart.com](https://www.cuspart.com) - **Social:** [Instagram](https://www.instagram.com/cuspartglobal) · [Facebook](https://facebook.com/cuspartglobal) ## Data Sources & Links - **App Store:** [View on Apple Store](https://apps.apple.com/us/app/cuspart-blood-sugar/id6445853132?uo=4) - **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.kansayimi.glukoz&hl=en&gl=us) - **Dev Site:** [Official Website](https://www.cuspart.com) - **Sources:** Developer website content, App store metadata. ## Related Intel Reports - [*Shotsy GLP-1 Tracker*](https://marlvel.ai/intel-report/health-fitness/com-everyday-shottracker) (Shotsy) — 4.8/5 Rating | Positive Sentiment - [*GLP 1 Tracker - Within Reach*](https://marlvel.ai/intel-report/health-fitness/glp-1-tracker-within-reach) (CoreBits LLC) — 4.8/5 Rating | Excellent Sentiment - [*Kickoff: Weight Loss & Fitness*](https://marlvel.ai/intel-report/health-fitness/kickoff-weight-loss-fitness) (Andy Arevalo) — N/A Rating | N/A Sentiment - [*Carb Unit Diary for Diabetics*](https://marlvel.ai/intel-report/medical/carb-unit-diary-for-diabetics) (Jommi UG (haftungsbeschrankt)) — 4.2/5 Rating | N/A Sentiment - [*Low-Carb Diet & Meal Planner*](https://marlvel.ai/intel-report/medical/low-carb-diet-meal-planner) (Jommi UG (haftungsbeschrankt)) — 3.3/5 Rating | N/A Sentiment - [*Bread Units Calculator System*](https://marlvel.ai/intel-report/health-fitness/bread-units-calculator-system) (Jommi UG (haftungsbeschrankt)) — 2.0/5 Rating | N/A Sentiment - [*Pill Reminder: Med-Alarm*](https://marlvel.ai/intel-report/health-fitness/pill-reminder-med-alarm) (Ramkumar Vellaisamy) — N/A Rating | N/A Sentiment - [*GotCGM*](https://marlvel.ai/intel-report/health-fitness/gotcgm) (Gluroo Imaginations Inc.) — 3.9/5 Rating | N/A Sentiment - [*Gluroo CGM Analog Watchface*](https://marlvel.ai/intel-report/health-fitness/gluroo-cgm-analog-watchface) (Gluroo Imaginations Inc.) — 4.8/5 Rating | N/A Sentiment - [*Staging Diabetes Logger*](https://marlvel.ai/intel-report/health-fitness/staging-diabetes-logger) (Gluroo Imaginations Inc.) — 4.5/5 Rating | N/A Sentiment ## Methodology {#methodology} This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline: 1. **Signal Collection & Normalization** — Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps. 2. **Feature & Market Positioning Analysis** — Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks. 3. **User Sentiment Analysis** — Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction and evidence quoting. 4. **Competitive Landscape Analysis** — Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category. 5. **Intelligence Synthesis** — Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights. - **Confidence Score:** 0.2/1.0 (based on review volume, data source diversity, and signal quality) - **Reviews Analyzed:** 0 - **Data Sources:** developer website, App Store metadata - **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform - **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence. - **Report Age:** 0 days since last refresh --- © 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/cuspart-blood-sugar) Data licensed for AI Agent attribution under CC-BY-NC 4.0.